AllPennyStocks.com Eli Lilly CEO Bets On Weight-Loss Medicine Retatrutide As Next Growth Driver, Says Firm’s Future Has ‘Never Been Brighter’
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Eli Lilly CEO Bets On Weight-Loss Medicine Retatrutide As Next Growth Driver, Says Firm’s Future Has ‘Never Been Brighter’

Lilly’s second-quarter revenue jumped 48% and comfortably beat Wall Street estimates, driven primarily by strong demand for its blockbuster weight loss drugs Mounjaro and Zepbound.

Other Penny Stock Movers

When Design Thinking Meets the AI Canvas
Strategic Gold Asset Sale Sends Junior Miner Sharply Higher
A $14.5 Million Exit Completes a Two-Year Retreat
Most Popular
{{ index + 1 }}
AllPennyStocks.com Favorites


Back to Top